On August 3rd, Tuopu Gene announced that it has completed nearly RMB 100 million Pre-B round of financing. This round of financing was led by Yuexiu Industry Fund.
Top gene was established in 2014 in Guangzhou, is a high-throughput sequencing is based on accurate tumor diagnosis and treatment as the core, focusing on the establishment of Chinese women accurate tumor diagnosis and treatment of the whole management platform of high-tech biomedical companies.
Top has three stock-owned or wholly-owned medical laboratories with high-throughput sequencing platforms for illumina and MGISEQ, digital PCR platforms, NanoString digital gene quantification systems, etc.; self-developed and built free-DNA (cfDNA) target capture technology (liquid biopsy), multiplex amplification technology, single molecule label noise reduction (UMI), tumor panel autonomous design, high performance computing (HPC) system and other technologies and platforms.
At present, the Tuopu gene has been laid out to Shenzhen Tuopu Renai Precision Medicine Research Institute, Zhongshan Tuopu Gene Medical Laboratory, Chengdu Tuopu Precision Medical Center, Hong Kong Tuopu Precision Medical Clinic, Tuopu Medical Technology (Europe) Co., Ltd. Pu-Gene Technology is the core closed-loop tumor precision medical ecosystem, which initially forms a “gene + referral†integrated service, a combination of “scientific research + clinical application†and a “gene + cell†dual-engine drive model to promote the clinical development of precision medical technology. Application and extension of the industrialization of the closed-loop tumor precision medical ecosystem.
As the leader of this round, Lu Rong, president of Yuexiu Industry Fund, said: With the promotion of PARP inhibitor drugs in the Chinese market and the CFDA's further recognition of NGS-based cancer multi-gene detection methods, huge female tumor-related The precision treatment market will be opened. Tuopu Gene has a strong precision medical clinical application promotion team, as the leader of women's cancer precision treatment platform, will quickly become the first brand in this field in the continuous market.
Yu Xiaobin, founder of Tuopu Gene, said: "After this round of financing, as the largest female tumor molecular diagnostic company in China, we will focus on promoting the iterative expansion of the closed-loop tumor precision medical ecosystem, and continuously expand the population of tumor tumor patients and their families. The entire health management platform service boundary continues to enhance the core competitiveness of Top's genes in the field of precision medicine."
For the future planning, Xiaobin proposed that Tuopu Gene as a leading enterprise focusing on women's cancer precision medical treatment will continue to increase investment in technology and hardware equipment, and in the precision of female tumors through cooperation and independent research and development. Provide more products and services in prevention and control, and at the same time give full play to the research advantages of Jinan University-Tupper Gene Joint Laboratory, develop and link all the nodes of precision medical health management services, including doctors, patients, pharmaceutical companies, insurance, etc. In all aspects, the individualized medical needs of cancer patients are maximized, allowing tumor patients to enjoy the most timely and appropriate services, and truly achieve "precise medical treatment."
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com